Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Batoclimab by Immunovant for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Likelihood of Approval
Batoclimab is under clinical development by Immunovant and currently in Phase II for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). According to...
Risk adjusted net present value: What is the current valuation of Immunovant's Batoclimab?
Batoclimab is a monoclonal antibody commercialized by Immunovant, with a leading Phase III program in Myasthenia Gravis. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of Immunovant's Batoclimab?
Batoclimab is a monoclonal antibody commercialized by Immunovant, with a leading Phase III program in Myasthenia Gravis. According to Globaldata,...